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Abstract 
Purpose: To determine occurrence and determinants of resistant hypertension (RHT) among patients 
attending cardiology clinic of the affiliated hospital of Hangzhou Normal University, China. 
Methods: An observational prospective cross-sectional study was conducted among patients with 
hypertension attending the cardiology clinic over a period of 6 months. After identification of patients 
with RHT, various independent co-variants were tested by logistic regression in order to evaluate the 
determinants of RHT. 
Results: Out of 556 patients, 104 (18.7 %) patients had RHT while 67 (12.1 %) patients had 
uncontrolled blood pressure (BP) in spite of treatment with three antihypertensive drugs including a 
diuretic; 37 (6.6 %) patients had controlled BP with > three drugs. Obesity (OR: 2.7, p = 0.002], duration 
of hypertension (OR: 1.8, p = 0.015], presence of diabetes mellitus (OR: 3.6, p < 0.001) and ischemic 
heart disease (OR: 3.2, p = 0.001) were significant determinants of resistant hypertension in the study 
cohort. 
Conclusion: The prevalence of RHT found in this study is significantly high, thus indicating a need for 
greater attention of clinicians to this highly morbid condition. Obese patients and those suffering from 
diabetes mellitus, ischemic heart disease and chronic diseases should be evaluated for the presence of 
RHT. Early identification of such patients will provide sufficient time for clinicians to refer patients, as 
well as modify and/or intensify therapy. 
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Hypertension is a growing problem, affecting 
about one billion people worldwide; among them 
two-thirds are from developing countries [1]. 
Alarmingly, it has been estimated that 1.56 billion 
adults will have hypertension in 2025 [1]. It is a 
leading cause of cardiovascular diseases (CVD) 
and kills 8 million people every year [2]. 
Hypertension leads to several disabling 
complications including cardiac failure (CF), 
retinopathy, stroke, chronic kidney disease 
(CKD) and atherosclerosis [3]. In order of avoid 
such complications and associated mortality, a 
stringent blood pressure (BP) control is 
mandatory but optimum  BP control has been 
observed only in 1/3 of patients receiving 
treatment. Such patients with poor BP control fall 
in the category of resistant hypertension [4]. 
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The term “resistant hypertension” refers to 
uncontrolled blood pressure in spite of the 
concurrent use of three antihypertensive drugs 
inclusive of a diuretic, prescribed at optimal 
dosage. It also includes patients whose blood 
pressure is controlled but with more than 3 
antihypertensive medications [5]. Resistance 
hypertension is contributed to several factors 
including old age, alcohol consumption, obesity, 
sodium intake, adherence and knowledge of 
therapy and limitation of treatment facilities [6]. 
Resistant hypertension is usually diagnosed with 
specialized techniques that are quite expensive 
and place economic burden on patients and 
health care systems. However, patients with 
resistance hypertension bear physical, mental 
and social disturbances as well.  Such patients 
are more likely to have CVD and end organ 
damage as compared to patients with controlled 
blood pressure [7]. Early recognition of 
hypertension along with appropriate therapy can 
reduce cardiovascular morbidity and mortality. 
 
Prevalence of hypertension in both developing 
and developed countries is nearly the same but 
blood pressure control rates in developing 
countries are lower than that of developed 
countries [8]. According to a recent investigation, 
prevalence of hypertension in China is 26.6 % 
and blood pressure is observed to be adequately 
controlled among 11.1 % patients only [9]. A 
great disparity in blood pressure (BP) control 
rates (27.6 – 46.0 %) among Chinese population 
has been observed in several studies and it 
might be contributed to methodological, 
geographical and population differences in these 
studies [10-12]. Several efforts have been made 
to identify possible risk factors of hypertension 
among Chinese population [10-12] but possible 
potential determinants of resistant hypertension 
are unclear in this region. On the other hand, 
more recently two studies described clinico-
laboratory characteristics and risk factors of 
resistant hypertension among Asian population 
[6,13]. More elaborative research is still needed 
in order to control resistant hypertension in this 
region.  In this context, we made an attempt to 
describe the prevalence and determinants of 
resistance hypertension in patients attending 
cardiology clinics of Hospital of Hangzhou 




Patients and study location 
 
An observational prospective cross-sectional 
study was conducted among patients attending 
cardiology follow-up clinics of Hospital of 
Hangzhou Normal University over a period of 6 
months (January 2013 – June 2013). All the 
patients with hypertension visiting cardiology 
clinics were identified by using clinic`s registers. 
Patients on regular follow-up were randomly 
selected for the study purpose. Only those 
patients who provided informed consent were 
included in the study. Patients who did not give 
written informed consent, attended clinic for the 
first time or less than 18 years of age were 
excluded from the study. All the patients included 
in current study were on regular follow-up and 





A structured data collection form was used to 
extract information regarding socio-
demographics, baseline illnesses, clinico-
laboratory parameters and treatment history. 
Two of the researchers (FC, KS) also interviewed 
patients after taking informed consents in order 
to assess their compliance with treatment, social 
and family history. On day of visit to the clinic, 
two blood pressure readings after an interval of 
ten minutes were recorded in addition to BP 
readings recorded by attending physician. 
Patient`s previous three readings of blood 
pressure were also recorded from their file. 
Patient`s height and weight were recorded to 




Hypertension in present study was defined as 
blood pressure ≥ 140/90 mmHg or use of anti-
hypertensive drugs. The term “resistance 
hypertension” refers to uncontrolled BP in spite 
use of three antihypertensive drugs (inclusive of 
at least one diuretic) or patients whose blood 
pressure is controlled with more than 3 drugs [5]. 
Chronic Kidney Disease (CKD) was defined as 
estimated GFR < 60 mL/min/1.73 m2 where 
eGFR was calculated by Cockroft-Gault formula. 
Diagnosis of diabetes mellitus (DM) was based 
on hyperglycemia recorded by attending clinician 
or was based on use of hypoglycemic agents. All 
other co-morbidities i.e. ischemic heart disease 
and hyperlipidemia were recorded if documented 
in patient`s file. Smokers were referred to 
patients who were currently smoking at least one 
cigarette per day. Alcohol consumption was 
defined as ≥1 alcoholic drink per month. Blood 
pressure goals or controlled BP in current study 
were <140/90 mmHg (patients without any co-
morbidities) or <130/90 mmHg (patients having 
DM and renal disease) [14]. BMI values ≥ 27.5 
kg/m2 were served to define obesity. Salt intake 
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was termed as high if daily sodium intake was 
greater than 3 mg/day (assessed by food history 
questionnaire).  
 
Medication record of all patients were retrieved 
from patient`s medical file. Drugs taken by all 
patients were categorized into following 
categories, Renin angiotensin aldosterone 
system (RAAS) inhibitors including  angiotensin 
receptor blockers (ARBs) and angiotensin 
converting enzyme inhibitors (ACEIs), beta 
blockers (BB), alpha blockers (AB), diuretics and 




A statistical package (SPSS, version 20) was 
used to analyze the data. Continuous variables 
were expressed as mean ± standard deviation 
(SD) if they were normally distributed while 
median and range were used if data had skewed 
distribution. Categorical data were presented as 
frequency with proportions. Continuous variables 
were compared between two groups (patients 
with and without resistant hypertension) using 
Student t-test while categorical variables were 
compared using Chi-square test or Fisher’s 
Exact test. Logistic regression was used to 
determine possible predictors of resistant 
hypertension. Statistically tested variables and 
those reported in previous literature were 
selected to assess their correlation with resistant 
hypertension. Variables with p < 0.25 in 
univariate were considered candidates for 
multivariate analysis and only significant 
variables (p < 0.05) in multivariate were 
considered final determinants of resistant 
hypertension [15,16]. Analysis was performed at 
95 % confidence interval and p < 0.05 was 
considered statistically significant. 
 
Ethical consideration  
 
This study was approved by the ethical 
committee of Hospital of Hangzhou Normal 
University (CASE451/HHNU/2012-A), and the 
final results as well as the manuscript were also 




A total of 1089 patients with hypertension 
attending regular cardiology clinics were 
selected. Out of the total selected patients, 533 
(49 %) patients were excluded from the study; 
321 patients refused to participate in the study, 
67 patients had very poor compliance with 
medications, 145 patients were visiting for the 
first time to the clinic. Finally, 556 (51 %) patients 




 Figure 1: Study methodology flow diagram 
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Table 1 describes the socio-demographics of the 
studied participants. About 60 % of patients had 
age > 60 years and gender was about equally 
distributed among patients (male: 56 %). The BP 
readings of all patients during last two visits at 
least one month apart were recorded and we 
found both systolic and diastolic blood pressures 
were high above target range in 212/556 (38.1 
%). Out of total 212 patients with uncontrolled 
BP, 67 (31.6 %) patients were using three 
antihypertensive medications inclusive of one 
diuretic. So the proportion of patients with 
uncontrolled BP among total study participants 
was 12.1 %. On the other hand, 37/556 (6.7 %) 
patients had controlled hypertension but were 
using 4 or more medications for their blood 
pressure control (thirteen patients were on 24 
drugs, ten on 5 drugs and three on 6 drugs).  
 
According to the definition of resistant 
hypertension (RHT) adopted in current study, 
104/556 (18.7 %) patients had resistant 
hypertension. A total 344/556 (61.9 %) had 
controlled blood pressure and among them 
111/344 were using three antihypertensive drugs 
inclusive of a diuretic and 98/344 (28.5 %) 
patients were using three drugs without diuretics 
while 37/344 (10.8 %) patients were using more 
than 3 antihypertensive drugs to control BP. 
Demographics, medications and baseline 
illnesses both patients with and without 
hypertension were compared in Table 1. 
Proportion of obesity was found to be 
significantly higher (p = 0.014) among patients 
with RHT. Similarly, patients with RHT had 
prolonged duration of hypertension than patients 
without RHT (p = 0.045). Only dyslipidemia was 
equally distributed among patients with and 
without RHT while all others co-morbid 
conditions were significantly higher among RHT 
group (Table 1). 
 
The compliance rate among patients with RHT 
was 100% while patients without RHT were also 
compliant (94 %) to their antihypertensive 
medications. The most commonly prescribed 
antihypertensive drugs were CCBs (61.9 %) and 
ACEIs (55.2 %).  The use of ACEIs, ARBs, BBs 
and diuretics was significantly higher among 
patients with RHT (Table 1). Most commonly 
prescribed diuretics in current study were 
furosemide, thiazide and spironolactone. Besides 
these antihypertensive medications, most 
commonly prescribed agents were anti-platelets 
(80 %), lipid lowering agents (39 %) and nitrates 
(40 %) as seen in this study. 
 
All the statistically tested variables (Table 1) and 
variables based on previous findings were 
subjected to logistic regression. Only four 
predictors in current study were found to be 
associated with resistant hypertension including 
obesity, duration of hospitalization and presence 
of diabetes mellitus and hypertension. 
 
Table 1: Comparison of social demographics, comorbidities and medication use between patients with and 
without resistant hypertension (RHT) 
 
Variable All patients 
N = 556 
Without RHT 
N = 452 
With RHT 
N = 104 
P-value 
Age (years, mean ± SD) 64.2 ± 7.8 63.6  ± 5.5 65.7 ± 11.4 0.762 
Male, n (%) 311 (56%) 256 (56.6%) 55 (52.9%) 0.167 
Obesity, n (%) 341 (61.3%) 267 (59.1%) 74 (71.2%) 0.014 
Smokers, n (%) 49 (8.8%) 40 (8.9%) 9 (8.7%) 0.692 
Alcohol users, n (%) 82 (14.8%) 65 (14.4%) 17 (16.3%) 0.159 
High salt intake, n (%) 65 (11.7%) 56 (12.4%) 9 (8.7%) 0.421 
Family history of hypertension 229 (41.1%) 182 (42.3%) 47 (45.2%) 0.665 
Duration of hypertension 10.3 ± 4.4 9.6 ± 5.7 11.8 ± 2.6 0.045 
Comorbidity  
DM, n (%) 266 (47.8%) 201 (44.5%) 65 (62.5%) 0.003 
CKD, n (%) 154 (27.2%) 113 (25%) 41 (39.4%) 0.020 
Dyslipidemia, n (%) 201 (36.2%) 169 (37.4%) 32 (30.8%) 0.072 
IHD, n (%) 388 (69.8%) 308 (68.1%) 86 (82.7%) 0.001 
Antihypertensive medication  
CCBs, n (%) 344 (61.9%) 273 (60.4%) 71 (68.3%) 0.063 
ACEIs, n (%) 307 (55.2%) 236 (52.2%) 71 (68.3%) 0.011 
ARBs, n (%) 178 (32%) 132 (29.2%) 46 (44.2%) 0.038 
Beta blockers, n (%) 230 (41.4%) 176 (39%) 54 (51.9%) 0.047 
Alpha blockers, n (%) 23 (4.1%) 17 (3.8%) 6 (5.8%) 0.288 
Diuretics, n (%) 221 (39.7%) 181 (36.5%) 40 (62.5%) <0.001 
DM: diabetes mellitus, CKD: chronic kidney disease, IHD: ischemic heart disease, CCBs: calcium channel 
blockers, ACEIs: angiotensin converting enzyme inhibitors, ARBs: angiotensin receptor blockers 
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Table 2: Determinants of resistant hypertension (RHT) by logistic regression (Multivariate analysis) 
 
Variable Adjusted Odds ratio 95% confidence interval P-value 
Age >60 years 2.2 1.4 to 4.7 0.092 
Obesity 2.7 1.1 to 7.8 0.002 
Longer duration of HTN* 1.8 0.9 to 5.2 0.015 
Smoking 1.1 0.3 to 4.5 0.317 
Alcohol use 0.9 0.5 to 2.7 0.198 
High salt intake 0.7 0.2 to 1.8 0.564 
DM 3.6 1.9 to 8.5 <0.001 
CKD 1.4 1.2 to 5.3 0.062 
IHD 3.2 2.6 to 11.4 0.001 
All the variables with p value 0.25 in univariate were subjected to multivariate analysis, Only CKD was found to 
be significant predictor in univariate [OR: 1.9 (0.7 to 2.6), p value: 0.022], *Longer duration of hypertension refer 





Resistant hypertension (RHT) portends 
significant burden to the patients and health care 
system in terms of cardiovascular events, hence 
it should be appropriately addressed during 
clinical practice. The prevalence of RHT in 
present study was 18.7 % which was comparable 
with findings of Asian study conducted in Sri 
Lanka by Kumara et al [6]. On the other hand, 
prevalence in current study was much higher 
than reported by Chia et al, another Asian study, 
conducted in Malaysia [13]. Study location might 
have contributed to difference in the prevalence. 
Chia et al enrolled patients from primary care 
setting. Mostly patients with controlled BP and 
with less severe conditions usually visit primary 
care facilities for regular checkup while severe 
and complicated patients prefer to visit 
secondary care settings [13,17,18].  
 
Ma et al reported very low prevalence (1.9 %) of 
RHT among hypertensive cohort HOT-CHINA 
study enrolling patients from 148 cities of 
mainland of China [19]. Wide difference of 
prevalence of RHT by Ma et al [19] than us might 
be contributed to several factors. Ma et al [19] 
excluded patients with new onset of heart 
disease and cerebrovascular disease. 
Additionally, the proportion of type 2 diabetes 
(about 25 %) among patients with RHT in his 
was very low while 62.5 % patients with RHT and 
44.5 % patients without RHT had diabetes 
mellitus in current study. On the other hand, 
treatment program used in HOT-CHINA study 
was strict and aimed to strengthen the blood 
pressure control that may lead to low prevalence 
of RHT in study conducted by Ma et al [19]. 
Previously published studies demonstrate wide 
disparity in their findings due to difference in 
population, definition of RHT used and 
methodology. These findings suggest the need of 
well-controlled clinical trials in order to determine 
accurate prevalence of RHT among Chinese 
population. 
 
Uncontrolled BP was observed in 212/556 (38.1 
%) patients in current study and among them 
67/212 (31.6 %) patients were classified as RHT.  
The rest (145/212, 68.4 %) patients had 
uncontrolled BP but did not fall under the 
category of RHT usually refer to uncontrolled or 
poorly controlled hypertension. Such 
hypertension is associated with several factors 
including poor compliance and inadequate 
therapy. In present study, overall uncontrolled 
HTN was observed in 26.1 % patients that might 
be contributed to patient`s failure to adhere with 
therapy (patient`s factor) or physician`s failure to 
intensify therapy (therapeutic or clinical inertia). 
As most of the patients in current study were 
compliant with their medications so it can be 
assumed that therapeutic or clinical inertia in 
present study is about 26 %. These findings are 
also consistent with previous reports [6]. A 
careful evaluation to differentiate therapeutic 
inertia from other causes of uncontrolled 
hypertension is of particular importance in clinical 
practice so that such patients could receive 
optimal therapy. 
 
Four determinants of RHT were observed in 
current study according to multivariate logistic 
regression. Obese patients were found to be 
associated with RHT by odds of 2.7 as compared 
to non-obese patients. It has been reported that 
obesity is associated with severe hypertension 
that increases number of treatments and reduces 
the rate of blood pressure control [5]. Similar 
findings were observed by Kumara et al [6]. 
Duration of hypertension was also found to be 
associated with RHT in present study.  Patients 
with longer duration of HTN (≥ 9 years) were 
more likely to be associated (OR: 1.8) with RHT 
and it is also in concordance with previous study 
[6]. It might be due to the reason that likelihood 
of more number of medications are usually 
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higher among patients with longer duration of 
hypertension thus increasing the chances to fall 
under the definition of resistant hypertension. 
More elaborative studies are required to evaluate 
impact of duration of hypertension on resistant 
hypertension. 
 
Several studies have identified co-morbidities as 
risk factor of resistant hypertension [4,6,13,18]. 
Patients with DM and IHD had more chances of 
having resistant hypertension in current study 
cohort. CKD was only found to be associated 
with RHT in unadjusted analysis which failed to 
demonstrate any association in adjusted 
analysis. It might be due to small sample size (n 
= 41) of patients having concurrent RHT and 
CKD. Hypertensive patients with DM had more 
likelihood (OR: 3.6) of having RHT than those 
without DM. Hypertensive diabetes patients have 
more chances of having diabetic complications 
which in turn aggravate hypertension disease 
and cause difficulty in blood pressure control 
[20]. 
 
Patients with both HTN and DM require strict 
treatment plan to reduce the risks of CVD and 
diabetic complications i.e. nephropathy. Renal 
deterioration was not evaluated in current study 
due to less number of patients with marked renal 
function disturbances. It might be due to referral 
of such patients to nephrology care unit while 
only patients attending cardiology clinic were 
enrolled in this study. Ischemic heart disease 
(IHD) was also found to be a significant 
determinant of RHT in present study and this 
finding is consistent with recent report [6].  
 
Recent 8th Joint National Committee (JNC) 
evidence-based guidelines for the management 
of high blood pressure in adults recommended 
initiation of therapy with thiazide diuretic, CCBs, 
ACEIs or ARBs, and if blood pressure is not 
controlled, then dosage of initial medications 
should be increased or a second medication 
should be added [4]. In present study, CCBs and 
ACEIs were frequently prescribed followed by 
beta blockers, ARBs, diuretics and alpha 
blockers. Most of the clinical trials showed that 
use of diuretics in management of HTN is an 
effective strategy to minimize the risks of stroke 
and cardiac diseases [21]. However diuretics 
were not commonly prescribed in present study 
even less than BBs (39.7 % vs 41.4 %). It has 
also been proved that BBs are not as good as 
other antihypertensive medications for the 
reduction of morbidity and mortality [22]. As the 
use of diuretics in current study was low and 
definition of RHT requires inclusion of diuretics in 
medications being used by the patients, it is 
possible that true prevalence in present study 
might be underestimated. 
 
Limitations of the study 
 
Some limitations observed with the study include 
the study period (6 months) therefore causalities 
among patients were not observed. Larger 
studies with regular follow-up are required in 
order to determine relationship of RHT with 
mortality. Being an observational study, decision 
on which different medications were used, was 
not ruled out. Additionally, hospitalization among 
patients solely related to hypertension and its 
associated complications is difficult to identify 
with this study design. Furthermore, there may 
be bias with the clinician with this study design. 
Stress levels among patients (that might be 
related to control of BP)] was not evaluate and 
severity of premorbid conditions were not 
evaluated in current study. But besides these 
limitations, present study contains several 
strengths including larger sample size. All the 
patients were interviewed to ensure that they 
were compliant to their medications and poorly 
compliant patients were excluded from the study. 
Thus, it can be assumed that chances of patients 
with uncontrolled hypertension due to non-




The findings of this study indicate that the high 
prevalence of resistant hypertension that 
underscore the need for physicians to give 
attention to identifying resistant hypertension 
much earlier. Patients with obesity, longer 
duration of hypertension, diabetes mellitus and 
ischemic heart disease are significantly 
associated with RHT. Such-high risk patients 
should be identified in a timely manner so that 
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